Khanyukov O. O., Zaiats I. O.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

. Coronary artery disease (CHD) is the most common cardiovascular disease in the world, the incidence of which increases with age. The prevalence of anemia also increases with age and is associated with a more severe condition in patients with CAD. This category of patients also has an increased risk of complications, including sudden cardiac death (RCD). Purpose: to evaluate the clinical and functional parameters of ischemia, the presence of pathological cardiac arrhythmias and the clinical efficacy of treatment with nitric oxide donors in patients with coronary artery disease and anemia. 95 patients with IHD were examined. The main group consisted of 53 IHD patients with iron deficiency anemia, which were divided into two subgroups. 24 patients of the first subgroup were recommended standard therapy for coronary artery disease and anemia. 29 patients of the second subgroup additionally took L-arginine. The control group consisted of 42 patients with coronary artery disease without anemia who received standard therapy. At the beginning of the study, the severity of ischemic changes and heart failure in patients of the main group was greater than in the control group. The median circadian heart rate index was less than normal in both groups, but in the main group this indicator was significantly lower. A greater average number of extraistols (both supraventricular and ventricular) was registered in the main group. The total number of patients with atrial fibrillation was also higher in the main group. During therapy, the indicator of «total ischemia burden» decreased in both groups and was comparable in the second subgroup (with L-arginine) and the control group (pk-2>0,05), but remained higher than the first subgroup (pk-1<0, 01; p1-2<0,05). The dynamics of the circadian index was similar: in all groups there was a decrease in CI HCC, but in the first subgroup the effect was lower than the control group and the second subgroup (pk-2>0,05; pk-1<0,01; p1-2<0,001). The number of extrasystoles decreased in both groups. The percentage of changes in the indicator of the number of extrasystoles in dynamics in the second subgroup was significantly higher than in the first, and then comparable with the indicator of the control group (pk-1<0,001; pk-2>0,05, pk-1<0,001).

ischemic heart disease,anemia,heart rhythm disorder,treatment.

1. WHO. WHO reveals leading causes of death and disability worldwide: 2000-2019 [Internet]. Available from: https://www.who.int/news/ item/09-12-2020-who-reveals-leading-causes-of-death-and-disability-worldwide-2000-2019.
2. WHO. World health statistics 2021: a visual summary [Internet]. Available from: https://www.who.int/data/gho/publications/world-healthstatistics.
3. WHO. WHO/Health topics/Cardiovascular diseases [Internet]. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
4. Derzhstat Ukrayiny, 1998-2022 [Internet]. Dostupno: https://ukrstat.gov.ua/ operativ/operativ2021/ds/kpops/arh_kpops2021_u.html.
5. Zheng J, Zheng D, Su T, Cheng J. Sudden Unexplained Nocturnal Death Syndrome: The Hundred Years’ Enigma. J Am Heart Assoc. 2018 Mar 3;7(5):e007837. DOI: 10.1161/JAHA.117.007837.
6. Hanyukov AA, Pesockaya LA, Sapozhnichenko LV, Pampuha AA. Rasprostranennost i patogenez anemii u pacientov s hronicheskoj serdechnoj nedostatochnostyu. Gematologiya. Transfuziologiya. Vostochnaya Evropa. 2021;7(2):219-228.
7. Sharma YP, Kaur N, Kasinadhuni G, Batta A, Chhabra P, Verma S, et al. Anemia in heart failure: still an unsolved enigma. Egypt Heart J. 2021 Aug 28;73(1):75. DOI: 10.1186/s43044-021-00200-6.
8. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, et al. Heart failure: preventing disease and death worldwide. ESC Heart Fail. 2014;1(1):4-25. DOI: 10.1002/ehf2.12005.
9. van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approachers. Nat Rev Cardiol. 2011;8(9):485-493. DOI: 10.1038/nrcardio.2011.77.
10. Culleton BF, Manns BJ, Zhang J, Tonelli M, Klarenbach S, Hemmelgarn BR. Impact of anemia on hospitalization and mortality in older adults. Blood. 2006 May 15;107(10):3841-6. DOI: 10.1182/blood-2005-10-4308.
11. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021 Feb 1;42(5):373-498. DOI: 10.1093/eurheartj/ehaa612.
12. Paolillo S, Scardovi AB, Campodonico J. Role of comorbidities in heart failure prognosis Part I: Anaemia, iron deficiency, diabetes, atrial fibrillation. Eur J Prev Cardiol. 2020 Dec;27(2):27-34. DOI: 10.1177/20474873209602 88.
13. Tanaka S, Kamiya K, Saito H, Saito K, Ogasahara Y, Maekawa E, et al. Prevalence and prognostic value of the coexistence of anaemia and frailty in older patients with heart failure. ESC Heart Fail. 2021 Feb;8(1):625-633. DOI: 10.1002/ehf2.13140.
14. Pizzini A, Aichner M, Sonnweber T, Tancevski I, Weiss G, Löffler-Ragg J. The Significance of iron deficiency and anemia in a real-life COPD cohort. Int J Med Sci. 2020 Aug 19;17(14):2232-2239. DOI: 10.7150/ijms.46163.
15. Goh VJ, Tromp J, Teng TK, Tay WT, Van Der Meer P, Ling LH, et al; ASIAN-HF investigators. Prevalence, clinical correlates, and outcomes of anaemia in multi-ethnic Asian patients with heart failure with reduced ejection fraction. ESC Heart Fail. 2018 Aug;5(4):570-578. DOI: 10.1002/ehf2.12279.
16. Anand IS, Gupta P. Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies. Circulation. 2018 Jul 3;138(1):80-98. DOI: 10.1161/CIRCULATIONAHA.118.030099.
17. Kiani FZ, Ahmadi A. Prevalence of different comorbidities in chronic obstructive pulmonary disease among Shahrekord PERSIAN cohort study in southwest Iran. Sci Rep. 2021 Jan 15;11(1):1548. DOI: 10.1038/s41598-020-79707-y.
18. Batchelor EK, Kapitsinou P, Pergola PE, Kovesdy CP, Jalal DI. Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment. J Am Soc Nephrol. 2020 Mar;31(3):456-468. DOI: 10.1681/ASN.2019020213.
19. Nowakowska M, Zghebi SS, Ashcroft DM, Buchan I, Chew-Graham C, Holt T, et al. The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Med. 2019 Jul 25;17(1):145. DOI: 10.1186/s12916-019- 1373-y.
20. Khan MA, Hashim MJ, Mustafa H, Baniyas MY, Al Suwaidi SKBM, AlKatheeri R, et al. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. Cureus. 2020;12(7):e9349. DOI: 10.7759/cureus.9349.
21. Meng H, Wang Y, Ruan J, Chen Y, Wang X, Zhou F, et al. Decreased Iron Ion Concentrations in the Peripheral Blood Correlate with Coronary Atherosclerosis. Nutrients. 2022 Jan 13;14(2):319. DOI: 10.3390/nu14020 319.
22. Stahl-Gugger A, de Godoi Rezende Costa Molino C, Wieczorek M, Chocano-Bedoya PO, Abderhalden LA, Schaer DJ, et al. Prevalence and incidence of iron deficiency in European community-dwelling older adults: an observational analysis of the DO-HEALTH trial. Aging Clin Exp Res. 2022 Sep;34(9):2205-2215. DOI: 10.1007/s40520-022-02093-0.
23. Martens P, Verbrugge FH, Nijst P, Dupont M, Mullens W. Limited contractile reserve contributes to poor peak exercise capacity in irondeficient heart failure. Eur J Heart Fail. 2018 Apr;20(4):806-808. DOI: 10.1002/ejhf.938.
24. Lanser L, Fuchs D, Scharnagl H, Grammer T, Kleber ME, März W, et al. Anemia of Chronic Disease in Patients With Cardiovascular Disease. Front Cardiovasc Med. 2021 Aug 12;8:666638. DOI: 10.3389/fcvm.2021.666638.
25. Rymer JA, Rao SV. Anemia and coronary artery disease: pathophysiology, prognosis, and treatment. Coron Artery Dis. 2018 Mar;29(2):161- 167. DOI: 10.1097/MCA.0000000000000598.
26. González-D’Gregorio J, Miñana G, Núñez J, Núñez E, Ruiz V, García-Blas S, et al. Iron deficiency and long-term mortality in elderly patients with acute coronary syndrome. Biomark Med. 2018 Sep;12(9):987-999. DOI: 10.2217/bmm-2018-0021.
27. Colombo MG, Kirchberger I, Amann U, Heier M, Thilo C, Kuch B, et al. Association between admission anemia and long-term mortality in patients with acute myocardial infarction: results from the MONICA/KORA myocardial infarction registry. BMC Cardiovasc Disord. 2018 Mar 9;18(1):50. DOI: 10.1186/s12872-018-0785-5.
28. Bobrov VO, Zharinov OY, Kuts VO, Sorokivskyy MS, Chernyaga-Royko UP, Tkhor NV, at al. Ambulatorne monitoruvannya EKG. Lviv: Vydavnytstvo «Medytsyna svitu»; 2004. s. 67. [in Ukrainian].
29. Abe H, Semba H, Takeda N. The Roles of Hypoxia Signaling in the Pathogenesis of Cardiovascular Diseases. J Atheroscler Thromb. 2017 Sep 1;24(9):884-894. DOI: 10.5551/jat.RV17009.
30. Zheng J, Zhou C, editors. Hypoxia and Human Diseases [Internet]. London: IntechOpen; 2017 [cited 2022 Aug 24]. Chapter 11, Hypoxia and Pulmonary Hypertension. Available from: https://www.intechopen.com/chapters/53817. DOI: 10.5772/67151.
31. Liu ML, Xing SJ, Liang XQ, Luo Y, Zhang B, Li ZC, et al. Reversal of Hypoxic Pulmonary Hypertension by Hypoxia-Inducible Overexpression of Angiotensin-(1-7) in Pulmonary Endothelial Cells. Mol Ther Methods Clin Dev. 2020 Apr 18;17:975-985.
32. Babapoor-Farrokhran S, Gill D, Alzubi J, Mainigi SK. Atrial fibrillation: the role of hypoxia-inducible factor-1-regulated cytokines. Mol Cell Biochem. 2021 Jun;476(6):2283-2293. DOI: 10.1007/s11010-021-04082-9.
33. Hanna RM, Streja E, Kalantar-Zadeh K. Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin. Adv Ther. 2021 Jan;38(1):52- 75. DOI: 10.1007/s12325-020-01524-6.
34. Kaplan JM, Sharma N, Dikdan S. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease. Int J Mol Sci. 2018 Jan 29;19(2):389. DOI: 10.3390/ijms19020389.
35. Ostrakhovitch EA, Tabibzadeh S. Homocysteine and age-associated disorders. Ageing Res Rev. 2019 Jan;49:144-164. DOI: 10.1016/j. arr. 2018.10.010.
36. Erkens R, Suvorava T, Sutton TR, Fernandez BO, Mikus-Lelinska M, Barbarino F, et al. Nrf2 Deficiency Unmasks the Significance of Nitric Oxide Synthase Activity for Cardioprotection. Oxid Med Cell Longev. 2018 Apr 30;2018:8309698. DOI: 10.1155/2018/8309698.
37. Zinellu A, Zinellu E, Pau MC, Fois AG, Mellino S, Piras B, et al. A systematic review and meta-analysis of homocysteine concentrations in chronic obstructive pulmonary disease. Clin Exp Med. 2022 May 5. DOI: 10.1007/s10238-022-00833-0.
38. Ahmad A, Dempsey SK, Daneva Z, Azam M, Li N, Li PL, et al. Role of Nitric Oxide in the Cardiovascular and Renal Systems. Int J Mol Sci. 2018 Sep 3;19(9):2605. DOI: 10.3390/ijms19092605.
39. Yalovenko MI, Khaniukov OO. Vybir optymalnoi medykamentoznoi terapii u khvorykh z fibryliatsiieiu peredserd i komorbidnoiu palohiieiu. Morphologia. 2018;12(4):104-115. DOI: 10.26641/1997-9665.2018.4.104-115. [in Ukrainian].
40. Totzeck M, Hendgen-Cotta UB, Rassaf T. Nitrite-Nitric Oxide Signaling and Cardioprotection. Adv Exp Med Biol. 2017;982:335-346. DOI: 10.1007/978-3-319-55330-6_18.
41. Tejero J, Shiva S, Gladwin MT. Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation. Physiol Rev. 2019 Jan 1;99(1):311-379. DOI: 10.1152/physrev.00036.2017.
42. Wu G, Meininger CJ, McNeal CJ, Bazer FW, Rhoads JM. Role of L-Arginine in Nitric Oxide Synthesis and Health in Humans. Adv Exp Med Biol. 2021;1332:167-187. DOI: 10.1007/978-3-030-74180-8_10.
43. Najafi H, Abolmaali SS, Heidari R, Valizadeh H, Jafari M, Tamaddon AM, et al. Nitric oxide releasing nanofibrous Fmoc-dipeptide hydrogels for amelioration of renal ischemia/reperfusion injury. J Control Release. 2021 Sep 10;337:1-13. DOI: 10.1016/j.jconrel.2021.07.016.
44. Cziráki A, Lenkey Z, Sulyok E, Szokodi I, Koller A. L-Arginine-Nitric Oxide-Asymmetric Dimethylarginine Pathway and the Coronary Circulation: Translation of Basic Science Results to Clinical Practice. Front Pharmacol. 2020 Sep 29;11:569914. DOI: 10.3389/ fphar.2020.569914.
45. Liu C, Liang MC, Soong TW. Nitric Oxide, Iron and Neurodegeneration. Front Neurosci. 2019 Feb 18;13:114. DOI: 10.3389/fnins.2019.00114.
46. Khaniukov OO, Zaiats IO. Vplyv donatoriv oksydu azotu na klinichnyi perebih ishemichnoi khvoroby sertsia z suputnoiu anemiieiu. Ukr Zh Med Biol Sport. 2022;3(37):192-199. DOI: 10.26693/jmbs07.03.192. [in Ukrainian].

«Bulletin of problems biology and medicine» Issue 3 (166), 2022 year, 277-282 pages, index UDK 616.12-005.4+616.155.194:546.172.6]-085.22-036.8

10.29254/2077-4214-2022-3-166-277-282